PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (18)
2024
-
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415
-
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)
Journal of Neuro-Oncology
2023
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
-
SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)
Clinical and Translational Oncology, Vol. 22, Núm. 2, pp. 171-186
2019
-
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet, Vol. 393, Núm. 10167, pp. 156-167
2017
-
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531
2016
-
GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status
Clinical and Translational Oncology, Vol. 18, Núm. 8, pp. 805-812
-
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137
2015
-
Mammographic density and breast cancer in women from high risk families
Breast Cancer Research, Vol. 17, Núm. 1
2014
-
SEOM guide to primary and secondary prevention of cancer: 2014
Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1072-1078
-
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
Clinical and Translational Oncology, Vol. 16, Núm. 3, pp. 273-279
2012
-
Hereditary pancreatic cancer: Molecular bases and their application in diagnosis and clinical management. A guideline of the TTD group
Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 553-563
2010
-
Extended-schedule dose-dense temozolomide in refractory gliomas
Journal of Neuro-Oncology, Vol. 96, Núm. 3, pp. 417-422
-
TTD consensus document on the diagnosis and management of hereditary colorectal cancer
Clinical and Translational Oncology, Vol. 12, Núm. 5, pp. 356-366
2009
-
Spanish society of medical oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
Clinical and Translational Oncology, Vol. 11, Núm. 7, pp. 446-454